The NIH/DAIDS Cross-Network (ACTG/HVTN/IMPAACT) TB Working Group calls for people living with HIV to be included in tuberculosis vaccine development.
A paper published in The Lancet HIV on 11 October 2022 recommends that people living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline.
Titled Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel, the paper’s recommendations are designed to shape the future of TB vaccine development and help ensure people living with HIV have access to safe and effective TB vaccines like those for the general population. Click here to read the paper.
The DAIDS Cross-Network TB Vaccine Working Group comprised of the HIV Vaccine Trials Network (HVTN), the AIDS Clinical Trials Group (ACTG), and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) worked collaboratively with the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) and its Division of AIDS.
Read the full press release here.
